Walvax沃森生物

CN
EN

Products List

Walvax has successfully developed 7 licensed vaccines, including recently approved 13-valent Pneumococcal Conjugate Vaccine (PCV13-TT), one of the most difficult vaccines to develop in the world.

 

Walvax proactively promotes PQ application of its products, and is proceeding with PQ application of 5 products. In 3 to 5 years, Walvax's WHO-PQ will yield fruitful results, which brings its internationalization to a higher level.

Quick Links

Pipeline
13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Prevention of invasive diseases caused by 13 serotypes of Streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age (below 6 years).

23-valent Pneumococcal Polysaccharide Vaccine

Prevention of invasive diseases caused by 23 serotypes of Streptococcus pneumoniae for use in individuals aged ≥ 2 years who are at increased risk of pneumococcal diseases.

Group ACYW135 Meningococcal Polysaccharide Vaccine

Prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A, C, Y and W135 for use in individuals aged ≥ 2 years.

Group A and C Meningococcal Polysaccharide Vaccine

Prevention of epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A and C for use in individuals aged ≥ 2 years.

Group A and Group C Meningococcal Conjugate Vaccine

Prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for use in infants and children 3 months through 5 years of age.

Haemophilus Influenzae Type b Conjugate Vaccine

Prevention of invasive infections caused by Haemophilus Influenzae type b for infants and children 2 months through 5 years of age.

Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, adsorbed

Prevention of pertussis, diphtheria and tetanus for infants and children 3 months through 6 years of age.